Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Amicus Therapeutics, Inc. (FOLD) had Revenue of $125.25M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$125.25M
Net Income	$-21.69M
Cost of Goods Sold	$11.70M
Gross Profit	$113.55M
Operating Expenses	$133.20M
Operating Income	$-7.95M
Non-Operating Income/Expense	$-10.09M
Pre-Tax Income	$-18.05M
Normalized Pre-Tax Income	$-18.05M
Income after Taxes	$-21.69M
Income from Continuous Operations	$-21.69M
Consolidated Net Income/Loss	$-21.69M
Normalized Income after Taxes	$-21.69M
EBIT	$-7.95M
EBITDA	$-5.51M
Weighted-Average Shares Outstanding (Basic)	307.69M
Weighted-Average Shares Outstanding (Diluted)	307.69M
Earnings per Share (EPS) (Basic)	$-0.07
Earnings per Share (EPS) (Diluted)	$-0.07
Balance Sheet Financials
Current Assets	$510.80M
Property, Plant, and Equipment	$28.72M
Long-Term Assets	$279.04M
Total Assets	$789.84M
Current Liabilities	$152.89M
Long-Term Debt	$390.71M
Long-Term Liabilities	$443.39M
Total Liabilities	$596.28M
Common Equity	$193.56M
Tangible Shareholders Equity	$-20.63M
Shareholders Equity	$193.56M
Common Shares Outstanding	307.92M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$7.76M
Cash Flow from Investing Activities	$-32.86M
Cash Flow from Financial Activities	$-11.70M
Beginning Cash	$216.72M
End Cash	$184.73M
Increase/Decrease in Cash	$-31.98M
Stock-Based Compensation	$25.17M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.34
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.67
Debt to Equity Ratio	2.02
Gross Margin	90.66%
Operating Margin	-6.35%
EBIT Margin	-6.35%
EBITDA Margin	--
Pre-Tax Profit Margin	-14.41%
Profit Margin	-17.31%
Free Cash Flow	$7.55M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.16
Inventory Turnover	0.09
Receiveable Turnover	1.42
Days Sales in Receivables	63.47
Return on Equity	-11.20%
Return on Tangible Equity	105.13%
Return on Assets	-2.75%
Return on Investments	-3.71%
Book Value Per Share	$0.63
Free Cash Flow per Share	$0.02
Operating Cash Flow per Share	$0.03

Data from Zacks Investment Research, Inc.